Solid Tumors

AbbVie is translating our expertise in hematologic malignancies to some of the most difficult-to-treat solid tumors.

Brain Cancer

Glioblastoma (GBM) is the most common and deadliest type of malignant primary brain tumor in adults.1  

GBM at a glance:

  • Approximately 11,000 people were diagnosed with GBM in the U.S. in 2017.2
  • GBM tumors are highly malignant and hard to treat because the cells reproduce quickly.3
  • Treatment options for GBM are limited, and available therapies have remained relatively unchanged for over 10 years.4

Learn more

Lung Cancer

Lung cancer is the leading cause of overall cancer-related mortality throughout the world.5

Non Small Cell Lung Cancer (NSCLC)

NSCLC is the most common type of lung cancer.6

NSCLC at a glance:

  • NSCLC comprises nearly 85% of all lung cancers and is associated with poor prognosis and limited treatment options.6,7,8
  • More than 75% of patients are diagnosed at an advanced stage (III or IV).9 5-year survival in patients with NSCLC is <20%.10

Small Cell Lung Cancer (SCLC)

SCLC is an aggressive, difficult-to-treat form of cancer where there have been few advancements over the years.11

SCLC at a glance:

  • SCLC accounts for approximately 13% of all lung cancers.12
  • The disease has an overall 5-year survival rate of <7%.12


Learn more

[1] Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol.2015;17 Suppl 4:iv1-iv62.
[2] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30.
[3] Korshunov A, Sycheva R, Golanov A. The prognostic relevance of molecular alterations in glioblastomas for patients <50. Cancer. 2005;104(4):825-832.
[4] Kazda T, Dziacky A, Burkon P, et al. Radiotherapy of Glioblastoma 15 Years after the Landmark Stupp's Trial: More Controversies than Standards?. Radiol Oncol. 2018;52(2):121–128. Published 2018 Jun 6. doi:10.2478/raon-2018-0023
[5] Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524-548.
[6] Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99:847-857.
[7] Cheng H, Zhang Z, Borczuk A, et al. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis. 2013;34(4):739-749.
[8] Johnson DH, Schiller JH, Bunn PA. Recent clinical advances in lung cancer management. J Clin Oncol. 2014;32(10):973-982.
[9] Slatore CG, Gould MK, Deffeback ME, White E. Lung cancer stage at diagnosis: individual associations in the prospective VITamins and lifestyle (VITAL) cohort. BMC Cancer.2011;11:228.
[10] Kelsey CR, Werner-Wasik M, Marks LB. Stage III lung cancer: two or three modalities? The continued role of thoracic radiotherapy. Oncology (Williston Park). 2006;20(10):1210-1219; discussion 1219, 1223, 1225.
[11] Koinis, Filippos; Kotsakis, Athanasios; Georgoulias, Vasileios. Transl Lung Cancer Res. 2016 Feb; 5(1): 39–50. Small Cell Lung Cancer (SCLC): No Treatment Advances in Recent Years. Accessed November 13, 2017. Available https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758968/
[12] Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2012. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER website, April 2015.